Subscribe To
Maxcyte to report first quarter 2023 financial results on may 10, 2023
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Maxcyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...
April 12, 2023, 4:05 pm
Humacyte (huma) completes enrollment in hav technology study
Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human a...
April 12, 2023, 2:25 pm
Broadwood partners now owns 33.3% of oncocyte
Fintel reports that Broadwood Partners has filed a 13D/A form with the SEC disclosing ownership of 57.13MM shares of Onco...
April 10, 2023, 10:23 pm
Incyte (incy) down 9.6% so far in 2023 on recent setbacks
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks....
April 5, 2023, 6:15 pm
Sutro biopharma reports full year 2022 financial results, business highlights and select anticipated milestones
– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quart...
March 30, 2023, 8:30 pm
Incyte's (incy) pemazyre gets approval to treat mlns in japan
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib)...
March 27, 2023, 1:45 pm
Fda rejection pushes incyte stock sharply lower
The shares of Incyte Corporation ( NASDAQ:INCY) are down 5.3% at $68.33 at last check, after the U.S...
March 24, 2023, 11:05 am
Humacyte, inc. (huma) reports q4 loss, misses revenue estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for th...
March 24, 2023, 9:57 am
Incyte stock dives on surprise rejection for updated jakafi
Incyte stock toppled Friday after the FDA unexpectedly rejected an extended-release version of its bloc...
March 24, 2023, 9:17 am
Incyte (incy) gets crl for jakafi extended-release tablets
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jak...
March 24, 2023, 8:26 am
Incyte (incy) receives fda approval for skin cancer treatment
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastat...
March 23, 2023, 1:44 pm
Humacyte to present fourth quarter and full year financial results and provide corporate update on march 24, 2023
DURHAM, N.C., March 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotec...
March 21, 2023, 8:01 am
Incyte (incy) vitiligo drug povorcitinib positive in phase ii
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vi...
March 20, 2023, 12:59 pm
Maxcyte, inc. (mxct) q4 2022 earnings call transcript
Maxcyte, Inc. (NASDAQ:MXCT ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Partici...
March 15, 2023, 9:41 pm
Double-digit sales growth: is this stock a convincing buy for growth investors?
Veracyte's revenue grew at a healthy clip in the fourth quarter. The genomic test company's financial h...
March 10, 2023, 9:30 am
Cardiol therapeutics says new study results highlight the cardioprotective effects of cannabidiol
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new study results have demonstrated the cardioprotective effects of pharmaceutically manufactur...
March 7, 2023, 12:22 pm
cytek biosciences, inc. (ctkb) q4 earnings top estimates
cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 40% and 3.07%, respectively,...
February 28, 2023, 9:05 pm
Vaxcyte, inc. (pcvx) q4 2022 earnings call transcript
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Part...
February 27, 2023, 10:03 pm
Veracyte to participate in upcoming investor conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc S...
February 27, 2023, 5:00 pm
Veracyte, inc. (vcyt) q4 2022 earnings call transcript
Start Time: 16:30 January 1, 0000 5:29 PM ET Veracyte, Inc. (NASDAQ:VCYT ) Q4 2022 Earnings Conference ...
February 23, 2023, 12:13 am